BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 28417853)

  • 21. PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin.
    Katal S; Gholamrezanezhad A; Kessler M; Olyaei M; Jadvar H
    PET Clin; 2018 Oct; 13(4):609-621. PubMed ID: 30219191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of
    Albano D; Zizioli V; Treglia G; Odicino F; Giubbini R; Bertagna F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):10-16. PubMed ID: 30396849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
    Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
    Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.
    Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M
    AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of fluorine-18-fluorodeoxyglucose-positron emission tomography/computed tomography as an effective method for staging in dogs with primary appendicular osteosarcoma.
    Crooks C; Randall E; Griffin L
    Vet Radiol Ultrasound; 2021 May; 62(3):350-359. PubMed ID: 33629412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. F-18-FDG PET-CT in children and young adults with Ewing sarcoma diagnosed in Norway during 2005-2012: a national population-based study.
    Johnsen B; Boye K; Rosendahl K; Biermann M; Trovik C; Aukland SM
    Clin Physiol Funct Imaging; 2016 Nov; 36(6):441-446. PubMed ID: 26039107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
    Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
    Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis.
    Kubo T; Furuta T; Johan MP; Ochi M
    Eur J Cancer; 2016 May; 58():104-11. PubMed ID: 26990930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma.
    Kandathil A; Subramaniam RM
    PET Clin; 2017 Oct; 12(4):475-488. PubMed ID: 28867117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected].
    Bestic JM; Peterson JJ; Bancroft LW
    Radiographics; 2009; 29(5):1487-500. PubMed ID: 19755607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic response as assessed by
    Harrison DJ; Chi YY; Tian J; Hingorani P; Mascarenhas L; McCowage GB; Weigel BJ; Venkatramani R; Wolden SL; Yock TI; Rodeberg DA; Hayes-Jordan AA; Teot LA; Spunt SL; Meyer WH; Hawkins DS; Shulkin BL; Parisi MT
    Cancer Med; 2021 Feb; 10(3):857-866. PubMed ID: 33340280
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Wang Z; Ma D; Yang J
    Hell J Nucl Med; 2016; 19(3):241-244. PubMed ID: 27824963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. (18)F-Fluorodeoxyglucose PET and PET/CT in Pediatric Musculoskeletal Malignancies.
    Grant FD; Drubach LA; Treves ST
    PET Clin; 2010 Jul; 5(3):349-61. PubMed ID: 27157839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing the interval between G-CSF therapy and F-18 FDG PET imaging in children and young adults receiving chemotherapy for sarcoma.
    Trout AT; Sharp SE; Turpin BK; Zhang B; Gelfand MJ
    Pediatr Radiol; 2015 Jul; 45(7):1001-6. PubMed ID: 25646737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of 18F-FDG PET/CT in soft tissue sarcoma.
    Sambri A; Bianchi G; Longhi A; Righi A; Donati DM; Nanni C; Fanti S; Errani C
    Nucl Med Commun; 2019 Jun; 40(6):626-631. PubMed ID: 30908341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of fluorodeoxyglucose positron emission tomography in malignancy of pulmonary artery mimicking pulmonary embolism.
    Lee EJ; Moon SH; Choi JY; Lee KS; Choi YS; Choe YS; Lee KH; Kim BT
    ANZ J Surg; 2013 May; 83(5):342-7. PubMed ID: 22943630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Combined functional and morphological imaging of sarcomas: significance for diagnostics and therapy monitoring].
    Schramm N; Schlemmer M; Rist C; Issels R; Reiser MF; Berger F
    Radiologe; 2010 Apr; 50(4):339-48. PubMed ID: 20221579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma.
    Ricard F; Cimarelli S; Deshayes E; Mognetti T; Thiesse P; Giammarile F
    Clin Nucl Med; 2011 Aug; 36(8):672-7. PubMed ID: 21716019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.